skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Snap-on SNA.us looked undervalued after price-weakness following its results reported about a month ago. Yet it is down 3.7% this morning. What am I missing? Fundamentals SEEM fine. I don't see fresh news today.

Is SNA a good longish term dividend grower with prospects of reasonable capital gain? Are you aware of any reason why it has kept dropping? Is debt the issue? Is it a falling knife—i.e. I am missing something important? Would you buy and why please?
Read Answer Asked by Adam on March 13, 2018
Q: I use Investorline. Help is sought in evaluating veracity of BMO-Morningstar Eq.Analysts reports: They contradict themselves:aMay 26,2017 FVE 86.00, March 13,2018 price 106.00
Feb 2018 analyst say:with share price close to our FVE we recommend not to add more
I feel these reports are not updated or not proof read or what else.???? Can you read it and comment pls
Art
Read Answer Asked by Arthur on March 13, 2018
Q: Hello,

How do you feel about Amazon's performance lately. Its obviously doing very well but do you think it will continue to perform like this or could you see a correction and price decrease in the near future? My shares have exploded and i'm glad to ride the wave but don't want to get caught in a bubble.

Do you think it will split?

Thanks!
Read Answer Asked by Harrison on March 13, 2018
Q: Qualcomm’s offer to buy NXPI is valued around $127.50. NXPI was trading at $125 a couple of days ago. It is at ~ $123.50 this morning 12 March.
There is considerable confusion over Broadcom (AVAGO) offer to buy QCOM. (I also own QCOM). There are reports today of US regulators fuming at AVGO due to alleged disregard of certain notices required by US regulators.

There are apparently also risks that China could block the sale of NXPI. I am fine keeping NXPI but not if the risk-reward is not in favor of private shareholders. Would you guess that the risk of a deal failure is higher than 50%? If NXPI is left at the altar, do you think NXPI would likely drop significantly in value--- say more than 20%--- or is it a good enough company that it will prosper on its own. Prosper means doing much better than just chugging along.

NXPI seems to be fair value even without M&A activity… Is it? would you buy more if you already had QCOM and NXPI? Would you sell NXPI? Or would you simply hold on.

NXPI seems to have an attractive business model and a good market position. Would it make an attractive target for a different buyer ... say an Intel?
Read Answer Asked by Adam on March 13, 2018
Q: Hello 5i
Please give me your thoughts on the above companies with regard to growth over the next 12-24 months. Which would you prefer?
Thank you so much for all your invaluable guidance!!
Dave
Read Answer Asked by Dave on March 12, 2018
Q: I have a well diversified CND and US portfolio. I have some US cash to deploy and currently own BAC, BIIB, GOOGL, AAPL, DWDP, FLIR, MS, SWKS and PYPL. I have a high risk tolerance and am looking for growth vs income. What would you top 3 US names be in order and what is your rational for the 3 picks. Thank you - Your advice has helped me become a better investor, GREAT service.
Scott
Read Answer Asked by Scott on March 12, 2018
Q: According to BloombergBusinessWeek , Cigna’s offer to buy ESRX.us includes $15 billion in debt, and Cigna will pay $48.75 in cash plus 0.2434 shares per Express Scripts share. That is approximately $96.03 per share , says Bloomberg. Yet in the past 2 days (8 and midday 9 March) ESRX shares have traded in the range US$79 – 85. This is noticeably lower than the offer valued at $96.

Do you see this as an opportunity to buy more ESRX? Or should an ESRX holder just wait and see? OR, do you think it is best to manage risk and sell ---even if price is 10 to 15% below current offer from Cigna. Is deal risk higher than most on this offer, given upheavels seen by pharmacy benefits managers and pharma chains like CVS?
Read Answer Asked by Adam on March 12, 2018
Q: I undertand that Irhythm Technologies, a US medical device/technology company, is far beyond the normal scope of your stock analysis. However it appears that the company is combining heart monitoring and analytics through a simple patch. This appears to be a significant development but...
I would appreciate your comments on the company if you venture into this sector of the market.
With gratitude for your assistance to retail investors.
Ed
Read Answer Asked by Ed on March 12, 2018
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!